Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Autophagy-Targeted Cancer Therapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ULK1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ULK1 Kinase Domain / Mutant Protein High purity (>95%), Endotoxin Controlled. Sequence Verified. Sf9/Insect expressed for active phosphorylation state. |
View ULK1 Products |
| Gene Delivery | ULK1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and cellular autophagy reporter assays. |
View ULK1 Products |
| Benchmark Ab | Anti-ULK1 Recombinant Antibody Recombinant positive control for Western Blot, IP, and IHC validation. |
View ULK1 Products |
| Validator | ULK1 siRNA Set For target knockdown and specificity verification in phenotypic assays. |
View ULK1 Products |
| Related Target A | ULK2 Homolog screening target to evaluate kinase selectivity and prevent off-target toxicity. |
View ULK2 Products |
| Related Target B | AMPK Upstream master regulator that phosphorylates and activates ULK1 under metabolic stress. |
View AMPK Products |
| Related Target C | mTOR Upstream negative regulator of ULK1; critical node in the autophagy initiation complex. |
View mTOR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| ULK1 vs ULK2 Kinase Selectivity | Highly purified recombinant ULK1 and ULK2 kinase domains available with >95% purity verified by SDS-PAGE. |
| Cellular Autophagy Pathway Validation | Lentiviral vectors expressing full-length ULK1 for stable cell line construction, enabling LC3-II and p62 flux monitoring. |
| Lack of Validated Screening Controls | Sequence-verified biosimilar antibodies and high-knockdown efficiency siRNA sets included in the assay validation toolkit. |
| Batch-to-Batch Activity Variation | Strict endotoxin control and sequence verification ensure reproducible enzymatic assays (ADP-Glo, TR-FRET). |
Live ULK1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ULK1 therapeutics is intensifying, with major players shifting focus from broad kinase profiling to highly selective small molecule inhibitors and PROTAC degraders. As first-generation autophagy inhibitors (like chloroquine derivatives) show limitations in potency, the next wave of R&D is targeting the initiation node of autophagy—the ULK1/2 complex—to overcome resistance to MAPK pathway inhibitors (KRAS, MEK, BRAF inhibitors).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Deciphera Pharmaceuticals, Compound Therapeutics | KRAS-mutant Colorectal & Pancreatic Cancer, NSCLC | Kinase Selectivity Assays (Need high-purity ULK1 and ULK2 proteins) |
| PROTAC Degraders | Academic Spin-offs, Biotech Startups | Advanced Solid Tumors, Drug-Resistant Cancers | Target Degradation Assays (Need Lentivirus for stable cell line expression) |
| Combination Therapies | Pfizer, Novartis (with MEK/KRAS inhibitors) | MAPK-inhibitor resistant tumors | Pathway validation (Need siRNA validation and phosphorylation-state controls) |